Infections were more common in the daclizumab HYP group than in the interferon beta-1a group ( in 65 % vs. 57 % of the patients , including serious infection in 4 % vs. 2 % ) , as were cutaneous events such as rash or eczema ( in 37 % vs. 19 % , including serious events in 2 % vs. < 1 % ) and elevations in liver aminotransferase levels that were more than 5 times the upper limit of the normal range ( in 6 % vs. 3 % ) .